NCT00327704

Brief Summary

Objective: To determine whether the early administration of albumin as an expander and antioxidant would improve survival on the 28th day for septic shock patients. Design: Prospective, multicenter, randomized, controlled versus saline, stratified on nosocomial infection and center. Setting: 27 Intensive Care Units (ICU) in France Coordinator: Pr J.P. Mira and Dr J. Charpentier - Cochin Hospital- Paris Patients: 800 patients could be included during the first 6 hours of their septic shock.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
794

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jul 2006

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 17, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 18, 2006

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2006

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
Last Updated

April 6, 2011

Status Verified

April 1, 2011

Enrollment Period

3.9 years

First QC Date

May 17, 2006

Last Update Submit

April 5, 2011

Conditions

Keywords

Septic Shock

Outcome Measures

Primary Outcomes (1)

  • Mortality, any cause, during the 28 day period after randomization

    day 28

Secondary Outcomes (6)

  • Evaluation of sequential organ failure assessment (SOFA) score

    ICU period

  • catecholamine free days

    day 28

  • incidence of nosocomial infection

    ICU period

  • mortality at 90 days

    day 90

  • length of ICU hospitalisation

    ICU discharge

  • +1 more secondary outcomes

Study Arms (2)

Albumin

ACTIVE COMPARATOR
Drug: albumin

Saline

PLACEBO COMPARATOR
Drug: saline

Interventions

albumin 20% 100 ml/8 hours for 3 days

Also known as: Vialebex
Albumin
salineDRUG

saline 100 ml/8hours for 3 days

Saline

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over 18 years old
  • Septic shock \< 6 hours
  • Agreement of patients

You may not qualify if:

  • Allergy to albumin
  • Weight \> 120 kg
  • Non septic shock
  • Burned
  • Cirrhosis
  • Albumin perfusion 48 hours before randomization
  • Pregnant women
  • Cardiac dysfunction New York Heart Association (NYHA) 3 or 4
  • Patients with therapeutic limitation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cochin Hospital

Paris, Paris, 75 014, France

Location

MeSH Terms

Conditions

Shock, Septic

Interventions

AlbuminsSodium Chloride

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Intervention Hierarchy (Ancestors)

ProteinsAmino Acids, Peptides, and ProteinsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Jean P Mira, Professor

    Cochin Hospital

    STUDY CHAIR
  • Julien Charpentier, Doctor

    Hôpital Cochin

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 17, 2006

First Posted

May 18, 2006

Study Start

July 1, 2006

Primary Completion

June 1, 2010

Study Completion

January 1, 2011

Last Updated

April 6, 2011

Record last verified: 2011-04

Locations